{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T06:02:04Z","timestamp":1790056924123,"version":"4.0.1"},"reference-count":60,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,16]],"date-time":"2023-08-16T00:00:00Z","timestamp":1692144000000},"content-version":"vor","delay-in-days":2784,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"Minnesota Partnership for Biotechnology and Medical Genomics","award":["89"],"award-info":[{"award-number":["89"]}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CA186976"],"award-info":[{"award-number":["CA186976"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CA180299"],"award-info":[{"award-number":["CA180299"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1007\/s13311-015-0407-1","type":"journal-article","created":{"date-parts":[[2015,11,30]],"date-time":"2015-11-30T11:59:06Z","timestamp":1448884746000},"page":"226-236","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["Improved Treatment Efficacy of Antiangiogenic Therapy when Combined with Picornavirus Vaccination in the GL261 Glioma Model"],"prefix":"10.1016","volume":"13","author":[{"given":"Danielle N.","family":"Renner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Courtney S.","family":"Malo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian F.","family":"Parney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin D.","family":"Pavelko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron J.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1007\/s13311-015-0407-1_bib1","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/nrn2175","article-title":"Angiogenesis in brain tumours","volume":"8","author":"Jain","year":"2007","journal-title":"Nat Rev Neurosci"},{"key":"10.1007\/s13311-015-0407-1_bib2","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s00109-013-1019-z","article-title":"Mechanisms of neovascularization and resistance to anti-angiogenic therapies in glioblastoma multiforme","volume":"91","author":"Soda","year":"2013","journal-title":"J Mol Med (Berl)"},{"key":"10.1007\/s13311-015-0407-1_bib3","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1126\/science.284.5422.1994","article-title":"Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF","volume":"284","author":"Holash","year":"1999","journal-title":"Science"},{"key":"10.1007\/s13311-015-0407-1_bib4","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/359843a0","article-title":"Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis","volume":"359","author":"Shweiki","year":"1992","journal-title":"Nature"},{"key":"10.1007\/s13311-015-0407-1_bib5","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/359845a0","article-title":"Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo","volume":"359","author":"Plate","year":"1992","journal-title":"Nature"},{"key":"10.1007\/s13311-015-0407-1_bib6","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1038\/362841a0","article-title":"Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo","volume":"362","author":"Kim","year":"1993","journal-title":"Nature"},{"key":"10.1007\/s13311-015-0407-1_bib7","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1046\/j.1365-2559.2001.01230.x","article-title":"Vascular endothelial growth factor expression correlates with tumour grade and vascularity in gliomas","volume":"39","author":"Chaudhry","year":"2001","journal-title":"Histopathology"},{"key":"10.1007\/s13311-015-0407-1_bib8","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1023\/A:1006333005563","article-title":"Vascular endothelial growth factor (VEGF) in astrocytic gliomas\u2013a prognostic factor?","volume":"45","author":"Oehring","year":"1999","journal-title":"J Neurooncol"},{"key":"10.1007\/s13311-015-0407-1_bib9","first-page":"4593","article-title":"Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders","volume":"57","author":"Presta","year":"1997","journal-title":"Cancer Res"},{"key":"10.1007\/s13311-015-0407-1_bib10","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1634\/theoncologist.2009-0121","article-title":"FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme","volume":"14","author":"Cohen","year":"2009","journal-title":"Oncologist"},{"key":"10.1007\/s13311-015-0407-1_bib11","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s11060-008-9745-8","article-title":"An exploratory survival analysis of anti-angiogenic therapy for recurrent malignant glioma","volume":"92","author":"Norden","year":"2009","journal-title":"J Neurooncol"},{"key":"10.1007\/s13311-015-0407-1_bib12","doi-asserted-by":"crossref","first-page":"4733","DOI":"10.1200\/JCO.2008.19.8721","article-title":"Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma","volume":"27","author":"Friedman","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1007\/s13311-015-0407-1_bib13","doi-asserted-by":"crossref","first-page":"4722","DOI":"10.1200\/JCO.2007.12.2440","article-title":"Bevacizumab plus irinotecan in recurrent glioblastoma multiforme","volume":"25","author":"Vredenburgh","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1007\/s13311-015-0407-1_bib14","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1093\/neuonc\/nor091","article-title":"A phase II trial of single-agent bevacizumab in patients with recurrent anaplastic glioma","volume":"13","author":"Kreisl","year":"2011","journal-title":"Neuro Oncol"},{"key":"10.1007\/s13311-015-0407-1_bib15","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJMoa1308345","article-title":"Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma","volume":"370","author":"Chinot","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1007\/s13311-015-0407-1_bib16","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1308573","article-title":"A randomized trial of bevacizumab for newly diagnosed glioblastoma","volume":"370","author":"Gilbert","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1007\/s13311-015-0407-1_bib17","doi-asserted-by":"crossref","first-page":"49","DOI":"10.2217\/cns.12.36","article-title":"Mechanisms of evasive resistance to anti-VEGF therapy in glioblastoma","volume":"2","author":"Lu","year":"2013","journal-title":"CNS Oncol"},{"key":"10.1007\/s13311-015-0407-1_bib18","first-page":"602812","article-title":"Bevacizumab improves quality of life in patients with recurrent glioblastoma","volume":"2011","author":"Nagpal","year":"2011","journal-title":"Chemother Res Pract"},{"key":"10.1007\/s13311-015-0407-1_bib19","doi-asserted-by":"crossref","first-page":"11393","DOI":"10.1073\/pnas.172398299","article-title":"VEGF-Trap: a VEGF blocker with potent antitumor effects","volume":"99","author":"Holash","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1007\/s13311-015-0407-1_bib20","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1200\/JCO.2009.22.9237","article-title":"Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors","volume":"28","author":"Lockhart","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1007\/s13311-015-0407-1_bib21","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s10456-011-9249-6","article-title":"Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab","volume":"15","author":"Papadopoulos","year":"2012","journal-title":"Angiogenesis"},{"key":"10.1007\/s13311-015-0407-1_bib22","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1167\/iovs.07-1175","article-title":"Interaction between bevacizumab and murine VEGF-A: a reassessment","volume":"49","author":"Yu","year":"2008","journal-title":"Invest Ophthalmol Visual Sci"},{"key":"10.1007\/s13311-015-0407-1_bib23","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/nrd1381","article-title":"Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer","volume":"3","author":"Ferrara","year":"2004","journal-title":"Nat Rev Drug Discov"},{"key":"10.1007\/s13311-015-0407-1_bib24","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1215\/15228517-2008-061","article-title":"VEGF Trap induces antiglioma effect at different stages of disease","volume":"10","author":"Gomez-Manzano","year":"2008","journal-title":"Neuro Oncol"},{"key":"10.1007\/s13311-015-0407-1_bib25","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1200\/JCO.2010.34.1636","article-title":"Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium study","volume":"29","author":"de Groot","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1007\/s13311-015-0407-1_bib26","doi-asserted-by":"crossref","first-page":"341","DOI":"10.3171\/2011.9.JNS11656","article-title":"A clinical trial of bevacizumab, temozolomide, and radiation for newly diagnosed glioblastoma","volume":"116","author":"Narayana","year":"2012","journal-title":"J Neurosurg"},{"key":"10.1007\/s13311-015-0407-1_bib27","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1093\/neuonc\/nop027","article-title":"Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice","volume":"12","author":"de Groot","year":"2010","journal-title":"Neuro Oncol"},{"key":"10.1007\/s13311-015-0407-1_bib28","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s11060-008-9718-y","article-title":"Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan","volume":"91","author":"Zuniga","year":"2009","journal-title":"J Neurooncol"},{"key":"10.1007\/s13311-015-0407-1_bib29","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/sj.neo.7900102","article-title":"Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption","volume":"2","author":"Rubenstein","year":"2000","journal-title":"Neoplasia"},{"key":"10.1007\/s13311-015-0407-1_bib30","first-page":"169","article-title":"Invasion as limitation to anti-angiogenic glioma therapy","volume":"88","author":"Lamszus","year":"2003","journal-title":"Acta Neurochir Suppl"},{"key":"10.1007\/s13311-015-0407-1_bib31","doi-asserted-by":"crossref","first-page":"3749","DOI":"10.1073\/pnas.1014480108","article-title":"Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma","volume":"108","author":"Keunen","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1007\/s13311-015-0407-1_bib32","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.ccr.2009.01.027","article-title":"Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis","volume":"15","author":"Paez-Ribes","year":"2009","journal-title":"Cancer Cell"},{"key":"10.1007\/s13311-015-0407-1_bib33","doi-asserted-by":"crossref","first-page":"572","DOI":"10.3171\/2008.7.JNS08475","article-title":"Flow cytometry and in vitro analysis of human glioma-associated macrophages. Laboratory investigation","volume":"110","author":"Parney","year":"2009","journal-title":"J Neurosurg"},{"key":"10.1007\/s13311-015-0407-1_bib34","doi-asserted-by":"crossref","first-page":"786","DOI":"10.2353\/ajpath.2009.081034","article-title":"Infiltrating CTLs in human glioblastoma establish immunological synapses with tumorigenic cells","volume":"175","author":"Barcia","year":"2009","journal-title":"Am J Pathol"},{"key":"10.1007\/s13311-015-0407-1_bib35","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.4049\/jimmunol.0902773","article-title":"CD8 T cell-initiated vascular endothelial growth factor expression promotes central nervous system vascular permeability under neuroinflammatory conditions","volume":"184","author":"Suidan","year":"2010","journal-title":"J Immunol"},{"key":"10.1007\/s13311-015-0407-1_bib36","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1172\/JCI60842","article-title":"Astrocyte-derived VEGF-A drives blood-brain barrier disruption in CNS inflammatory disease","volume":"122","author":"Argaw","year":"2012","journal-title":"J Clin Invest"},{"key":"10.1007\/s13311-015-0407-1_bib37","doi-asserted-by":"crossref","first-page":"6551","DOI":"10.1158\/1078-0432.CCR-09-1067","article-title":"Systemic inhibition of transforming growth factor-beta in glioma-bearing mice improves the therapeutic efficacy of glioma-associated antigen peptide vaccines","volume":"15","author":"Ueda","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1007\/s13311-015-0407-1_bib38","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1097\/CJI.0b013e318209eed4","article-title":"Topical imiquimod has therapeutic and immunomodulatory effects against intracranial tumors","volume":"34","author":"Xiong","year":"2011","journal-title":"J Immunother"},{"key":"10.1007\/s13311-015-0407-1_bib39","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1007\/s00262-011-1069-4","article-title":"A critical role for regulatory T cells in driving cytokine profiles of Th17 cells and their modulation of glioma microenvironment","volume":"60","author":"Cantini","year":"2011","journal-title":"Cancer Immunol Immunother"},{"key":"10.1007\/s13311-015-0407-1_bib40","first-page":"2394","article-title":"Studies on the chemotherapy of experimental brain tumors: development of an experimental model","volume":"30","author":"Ausman","year":"1970","journal-title":"Cancer Res"},{"key":"10.1007\/s13311-015-0407-1_bib41","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s00262-010-0946-6","article-title":"Experimental immunotherapy for malignant glioma: lessons from two decades of research in the GL261 model","volume":"60","author":"Maes","year":"2011","journal-title":"Cancer Immunol Immunother"},{"key":"10.1007\/s13311-015-0407-1_bib42","doi-asserted-by":"crossref","first-page":"613","DOI":"10.4049\/jimmunol.1201557","article-title":"Vaccine injection site matters: qualitative and quantitative defects in CD8 T cells primed as a function of proximity to the tumor in a murine glioma model","volume":"190","author":"Ohlfest","year":"2013","journal-title":"J Immunol"},{"key":"10.1007\/s13311-015-0407-1_bib43","doi-asserted-by":"crossref","first-page":"e0125565","DOI":"10.1371\/journal.pone.0125565","article-title":"Effective treatment of established GL261 murine gliomas through picornavirus vaccination-enhanced tumor antigen-specific CD8+ T cell responses","volume":"10","author":"Renner","year":"2015","journal-title":"PLoS One"},{"key":"10.1007\/s13311-015-0407-1_bib44","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1038\/mt.2013.52","article-title":"The epitope integration site for vaccine antigens determines virus control while maintaining efficacy in an engineered cancer vaccine","volume":"21","author":"Pavelko","year":"2013","journal-title":"Mol Ther"},{"key":"10.1007\/s13311-015-0407-1_bib45","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.4049\/jimmunol.1200658","article-title":"CD8 T cell-initiated blood-brain barrier disruption is independent of neutrophil support","volume":"189","author":"Johnson","year":"2012","journal-title":"J Immunol"},{"key":"10.1007\/s13311-015-0407-1_bib46","first-page":"241","article-title":"Neuroimaging of demyelination and remyelination models","volume":"318","author":"Pirko","year":"2008","journal-title":"Curr Top Microbiol Immunol"},{"key":"10.1007\/s13311-015-0407-1_bib47","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1186\/1471-2407-10-252","article-title":"Effects of bevacizumab plus irinotecan on response and survival in patients with recurrent malignant glioma: a systematic review and survival-gain analysis","volume":"10","author":"Xu","year":"2010","journal-title":"BMC Cancer"},{"key":"10.1007\/s13311-015-0407-1_bib48","doi-asserted-by":"crossref","first-page":"5664","DOI":"10.1158\/1078-0432.CCR-10-1564","article-title":"Heterogeneous blood-tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer","volume":"16","author":"Lockman","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1007\/s13311-015-0407-1_bib49","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1158\/1078-0432.CCR-10-2563","article-title":"Gene expression profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy","volume":"17","author":"Prins","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1007\/s13311-015-0407-1_bib50","doi-asserted-by":"crossref","first-page":"5955","DOI":"10.1158\/0008-5472.CAN-07-5973","article-title":"Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients","volume":"68","author":"Wheeler","year":"2008","journal-title":"Cancer Res"},{"key":"10.1007\/s13311-015-0407-1_bib51","doi-asserted-by":"crossref","first-page":"3466","DOI":"10.1158\/0008-5472.CAN-14-0296","article-title":"Autologous T-cell therapy for cytomegalovirus as a consolidative treatment for recurrent glioblastoma","volume":"74","author":"Schuessler","year":"2014","journal-title":"Cancer Res"},{"key":"10.1007\/s13311-015-0407-1_bib52","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1080\/01616412.1991.11739964","article-title":"Correlation between magnetic resonance imaging and histopathology of intracranial glioma","volume":"13","author":"Iwama","year":"1991","journal-title":"Neurol Res"},{"key":"10.1007\/s13311-015-0407-1_bib53","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.3174\/ajnr.A3106","article-title":"Differentiation between brain glioblastoma multiforme and solitary metastasis: qualitative and quantitative analysis based on routine MR imaging","volume":"33","author":"Chen","year":"2012","journal-title":"AJNR Am J Neuroradiol"},{"key":"10.1007\/s13311-015-0407-1_bib54","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/BF00146086","article-title":"Prognostic significance of preoperative MRI scans in glioblastoma multiforme","volume":"27","author":"Hammoud","year":"1996","journal-title":"J Neurooncol"},{"key":"10.1007\/s13311-015-0407-1_bib55","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/2045-8118-12-5","article-title":"Vascular endothelial growth factor blockade alters magnetic resonance imaging biomarkers of vascular function and decreases barrier permeability in a rat model of lung cancer brain metastasis","volume":"12","author":"Pishko","year":"2015","journal-title":"Fluids Barriers CNS"},{"key":"10.1007\/s13311-015-0407-1_bib56","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1093\/neuonc\/noq150","article-title":"Dynamic magnetic resonance imaging assessment of vascular targeting agent effects in rat intracerebral tumor models","volume":"13","author":"Muldoon","year":"2011","journal-title":"Neuro Oncol"},{"key":"10.1007\/s13311-015-0407-1_bib57","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.ccr.2008.01.034","article-title":"HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion","volume":"13","author":"Du","year":"2008","journal-title":"Cancer Cell"},{"key":"10.1007\/s13311-015-0407-1_bib58","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1158\/2326-6066.CIR-14-0053","article-title":"Bevacizumab plus ipilimumab in patients with metastatic melanoma","volume":"2","author":"Hodi","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"10.1007\/s13311-015-0407-1_bib59","doi-asserted-by":"crossref","first-page":"e24436","DOI":"10.4161\/onci.24436","article-title":"The immunomodulatory effects of bevacizumab on systemic immunity in patients with metastatic melanoma","volume":"2","author":"Mansfield","year":"2013","journal-title":"Oncoimmunology"},{"key":"10.1007\/s13311-015-0407-1_bib60","doi-asserted-by":"crossref","first-page":"17561","DOI":"10.1073\/pnas.1215397109","article-title":"Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy","volume":"109","author":"Huang","year":"2012","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-015-0407-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13311-015-0407-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923009534?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923009534?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-015-0407-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-015-0407-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T06:50:25Z","timestamp":1761807025000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747923009534"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":60,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["S1878747923009534"],"URL":"https:\/\/doi.org\/10.1007\/s13311-015-0407-1","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2016,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Improved Treatment Efficacy of Antiangiogenic Therapy when Combined with Picornavirus Vaccination in the GL261 Glioma Model","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s13311-015-0407-1","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 The American Society for Experimental NeuroTherapeutics, Inc. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}